About 1,195 results

ALLMedicine™ Noonan Syndrome Center

Research & Reviews  462 results

Targeting SHP2 phosphatase in hematological malignancies.
Expert Opinion on Therapeutic Targets; Kanumuri R, Kumar Pasupuleti S et. al.

May 4th, 2022 - Src homology-2-containing protein tyrosine phosphatase 2 (SHP2) is a ubiquitously expressed, non-receptor protein tyrosine phosphatase encoded by the PTPN11 gene. Gain-of-function (GOF) mutations in PTPN11 are associated with the development of va...

Cardiac features of Noonan syndrome in Japanese patients.
Cardiology in the Young; Ichikawa Y, Kuroda H et. al.

Apr 28th, 2022 - Cardiovascular disease is one of the most important problems in long-term follow-up for Noonan syndrome. We examined cardiovascular issues and clinical manifestations, with a focus on the cardiovascular disease and prognosis of patients with Noona...

Noonan Syndrome

Apr 22nd, 2022 - Practice Essentials Noonan syndrome is a genetic disorder that prevents normal development of various parts of the body. The cardinal features of Noonan syndrome include unusual facies (ie, hypertelorism, down-slanting eyes, webbed neck), congenit...

The down-regulation of tyrosine phosphatase SHP2 activity is involved in the removal of...
Neuroscience Letters; Zhou H, Xie Y et. al.

Apr 20th, 2022 - Hebbian-type synaptic plasticity which includes long term potentiation (LTP) and long term depression (LTD), is the main cellular mechanism underlying learning and memory. Effective activity and synaptic content of tyrosine phosphatase SHP2 are re...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  4 results

Constitution of a Biological Collection to Study the Pathophysiology in Noonan Syndrome

Apr 1st, 2022 - Noonan syndrome is a rare autosomal dominant genetic disorder characterized by a combination of typical facial features, heart defects, short stature, skeletal abnormalities, mild developmental delay and a predisposition to myeloproliferative diso...

Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome)

Feb 3rd, 2022 - The purpose of this study is to collect information about safety and effectiveness for long term use of Norditropin®. Participants will attend the medical institution according to usual practice and receive medical care, as agreed with the study d...

Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome

Nov 9th, 2020 - Noonan syndrome (NS) is a relatively frequent autosomal dominant disorder characterised by facial dysmorphic features, heart defects, developmental delay, and short stature. This syndrome is mostly caused by gain-of-function mutations in the PTPN1...

Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome

Aug 10th, 2020 - This trial is conducted in Asia. The aim of the trial is to investigate the long-term efficacy and safety of two doses of NN-220 (somatropin) in short stature due to Noonan syndrome.

see more →

News  9 results

Novel Mutation May Be Unrecognized Cause of Sudden Infant Death

Aug 24th, 2021 - A previously healthy infant who survived sudden cardiac arrest at home was later found to have a de novo likely pathogenic genetic mutation in the SOS1 gene, which might be an unrecognized cause of sudden infant death, report clinicians from Misso...

2021 Update on sequencing in prenatal genetics
Rebecca Reimers, MD, Stephanie Guseh, MD

Apr 12th, 2021 - Prenatal diagnosis has expanded from identification of aneuploidy to include copy number variants detected on microarray (such as 22q11 deletion syndrome) and now single-gene disorders identified by targeted or exome and genome sequencing. How and.

Findings may inform design of new treatments for JMML
HT Staff

Oct 9th, 2015 - Colony of iPSCs Image from the Salk Institute Researchers have used induced pluripotent stem cells (iPSCs) to model juvenile myelomonocytic leukemia (JMML) and gain new insight into the disease. The team noted that somatic PTPN11 mutations are kno.

Team care recommended for pregnant women with genetic conditions
MDedge ObGyn; Shannon Aymes

Sep 22nd, 2015 - The American College of Obstetricians and Gynecologists is calling on ob. gyns.

FDA Warns of Possible Increased Risk for Death With Somatropin

Dec 23rd, 2010 - December 23, 2010 — The US Food and Drug Administration (FDA) is looking into results from a French study that found that persons with idiopathic growth hormone deficiency and idiopathic or gestational short stature who were treated with long-term...

see more →

Patient Education  2 results see all →